Recent investigations have centered on the convergence of glucagon-like peptide-1|glucose-dependent insulinotropic polypeptide|GCGR agonist therapies and dopaminergic communication. While GIP agonists are commonly employed for managing type 2 diabetes, their emerging impacts on reinforcement circuits, specifically influenced by dopaminergic network